Sitagliptin and cardiovascular outcomes in type 2 diabetes - author's reply

Ähnliche Einträge

• Correspondence on sitagliptin and cardiovascular outcomes in type 2 diabetes
  von: Holman, R, et al.
  Veröffentlicht: (2015)
• Cardiovascular outcome trials of glucose-lowering strategies in type 2 diabetes--Authors' reply.
  von: Holman, R, et al.
  Veröffentlicht: (2014)
• Effect of sitagliptin on kidney function and respective cardiovascular outcomes in type 2 diabetes: Outcomes from TECOS.
  von: Cornel, J, et al.
  Veröffentlicht: (2016)
• Blood pressure reduction and major cardiovascular events in people with and without type 2 diabetes - authors' reply
  von: Nazarzadeh, M, et al.
  Veröffentlicht: (2022)
• Assessing the safety of sitagliptin in older participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
  von: Bethel, M, et al.
  Veröffentlicht: (2017)